Cargando…

TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma

BACKGROUND: Although the molecular features of pancreatic ductal adenocarcinoma (PDAC) have been well described, the impact of detailed gene mutation subtypes on disease progression remained unclear. This study aimed to evaluate the impact of different TP53 mutation subtypes on clinical characterist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yiran, Jin, Jiabin, Ji, Yuchen, Zhang, Jiaqiang, Fu, Ningzhen, Chen, Mengmin, Wang, Jun, Qin, Kai, Jiang, Yu, Cheng, Dongfeng, Deng, Xiaxing, Shen, Baiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691048/ https://www.ncbi.nlm.nih.gov/pubmed/38037073 http://dx.doi.org/10.1186/s12967-023-04742-y

Ejemplares similares

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
por: Fu, Ningzhen, et al.
Publicado: (2022)

Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis
por: Weng, Yuanchi, et al.
Publicado: (2020)

Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients
por: Fu, Ningzhen, et al.
Publicado: (2021)

Risk factors for and prognostic values of postoperative acute kidney injury after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A retrospective, propensity score‐matched cohort study of 1312 patients
por: Ji, Yuchen, et al.
Publicado: (2022)

Accuracy of Nodal Positivity in Inadequate Lymphadenectomy in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Population Study Using the US SEER Database
por: Wang, Weishen, et al.
Publicado: (2019)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

KRAS(G12D) and TP53(R167H) Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs
por: Principe, Daniel R., et al.
Publicado: (2018)

KRAS, KIT and TP53 mutations in mother’s and daughter’s gastric cardia adenocarcinomas
por: Gluszek, Stanislaw, et al.
Publicado: (2018)

The impact of Omicron pandemic and COVID‐19 vaccination on the pancreatic adenocarcinoma patients
por: Fu, Ningzhen, et al.
Publicado: (2022)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Real‐world implications of nonbiological factors with staging, clinical management, and prognostic prediction in pancreatic ductal adenocarcinoma
por: Wang, Chao, et al.
Publicado: (2022)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)

Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis
por: Hung, Wei-Chia, et al.
Publicado: (2020)

Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma
por: Wen, Chenlei, et al.
Publicado: (2020)

Worth it or not? Primary tumor resection for stage IV pancreatic cancer patients: A SEER‐based analysis of 15,836 cases
por: Fu, Ningzhen, et al.
Publicado: (2021)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Limited importance of the dominant-negative effect of TP53 missense mutations
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2011)

Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection
por: Chen, Haoda, et al.
Publicado: (2021)

Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
por: Hori, Yasuki, et al.
Publicado: (2015)

Differentiating TP53 Mutation Status in Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI-Derived Radiomics
por: Gao, Jing, et al.
Publicado: (2021)

Health‐related quality of life and survival outcomes for patients with major depressive disorder and anxiety: A longitudinal study in pancreatic ductal adenocarcinoma
por: Ji, Yuchen, et al.
Publicado: (2023)

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study
por: Zou, Siyi, et al.
Publicado: (2022)

Correction: Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
Publicado: (2015)

p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma
por: Rodrigues, Joana M., et al.
Publicado: (2020)

Minimally invasive distal pancreatectomy for PNETs: laparoscopic or robotic approach?
por: Zhang, Jiaqiang, et al.
Publicado: (2017)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

The role of TP53 gain-of-function mutation in multifocal glioblastoma
por: Olafson, Lauren R., et al.
Publicado: (2020)

Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma
por: Das, Sunetra, et al.
Publicado: (2021)

Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene
por: Doffe, Flora, et al.
Publicado: (2020)

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
por: Schabath, Matthew B., et al.
Publicado: (2015)

Quadruplicate Synchronous Adenocarcinoma of the Colon with Distant Metastases—Long-Term Molecular Follow-Up by KRAS and TP53 Mutational Profiling
por: Bádon, Emese Sarolta, et al.
Publicado: (2020)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_urfuk73g5o859oo68lsbi0use5